Pharma Industry News

FDA green light for BMS, bluebird bio’s CAR-T therapy Abecma in multiple myeloma

CAR-T therapy cleared for use in adults with relapsed or refractory multiple myelomaOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]